Michael Grissinger
Director/Board Member chez AKARI THERAPEUTICS, PLC
Fortune : 55 345 $ au 31/07/2023
Profil
Michael Grissinger currently works at Kira Biotech Pty Ltd., as Chairman from 2020, Atrin Pharmaceuticals LLC, as Director from 2018, Akari Therapeutics Plc, as Independent Director from 2018, Aprea Therapeutics, Inc., as Independent Director from 2022, Atriva Therapeutics GmbH, as Director from 2020, and Envisagenics, Inc., as Director.
Mr. Grissinger also formerly worked at resTORbio, Inc., as Independent Director from 2018 to 2020, Atrin Pharmaceuticals, Inc., as Director, Janssen Pharmaceuticals, Inc., as Member-Management Board, Johnson & Johnson Ltd., as Vice President-Divestitures, M&A Operations from 1996 to 2018, and Johnson & Johnson, as VP & Head-Pharmaceutical Corporate Development.
Mr. Grissinger received his undergraduate degree from Juniata College and Masters Business Admin degree from Fox School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AKARI THERAPEUTICS PLC
0,20% | 01/01/2024 | 20 000 000 ( 0,20% ) | 50 000 $ | 31/07/2023 |
APREA THERAPEUTICS, INC.
0,01% | 23/08/2023 | 799 ( 0,01% ) | 5 345 $ | 31/03/2024 |
Postes actifs de Michael Grissinger
| Sociétés | Poste | Début |
|---|---|---|
| AKARI THERAPEUTICS, PLC | Director/Board Member | 23/01/2018 |
| APREA THERAPEUTICS, INC. | Director/Board Member | 01/05/2022 |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Director/Board Member | 01/11/2018 |
Kira Biotech Pty Ltd.
 Kira Biotech Pty Ltd. BiotechnologyHealth Technology Kira Biotech Pty Ltd. operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders. The company was founded by Georgina Clark is headquartered in Brisbane, Australia. | Chairman | 30/07/2020 |
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Director/Board Member | 01/12/2020 |
Envisagenics, Inc.
 Envisagenics, Inc. BiotechnologyHealth Technology Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY. | Director/Board Member | - |
Anciens postes connus de Michael Grissinger
| Sociétés | Poste | Fin |
|---|---|---|
| ADICET BIO, INC. | Director/Board Member | 15/09/2020 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01/01/2018 |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Director/Board Member | - |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Michael Grissinger
| Juniata College | Undergraduate Degree |
| Fox School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| AKARI THERAPEUTICS, PLC | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Health Technology |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
Envisagenics, Inc.
Envisagenics, Inc. BiotechnologyHealth Technology Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Kira Biotech Pty Ltd.
Kira Biotech Pty Ltd. BiotechnologyHealth Technology Kira Biotech Pty Ltd. operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders. The company was founded by Georgina Clark is headquartered in Brisbane, Australia. | Health Technology |
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
